TeleSoftas is an IT services company operating in Lithuania that has started cooperating with Congenica – developers of the world’s leading automated decision support platform for the analysis of genomic data. This IT partnership is designed to further develop the platform’s functionalities, allowing for faster and more accurate research of genetic diseases at scale. In implementing this project, the Lithuanian company will expand and intends to attract new IT specialists.
Cambridge-based Congenica develops the world’s leading automated clinical decision support platform for research use. It is used today by global healthcare organisations, centres of excellence, diagnostic laboratories and biopharmaceutical companies. Congenica also provides an exclusive analysis of rare genetic diseases for the UK Genomic Medicine Service – the first national healthcare system to offer whole genome sequencing as part of routine care. This platform allows researchers to shorten the analysis and interpretation of genetic diseases to as little as 5-minutes, which in the past would take on average over 20-hours. Thus, the platform is helping more people to receive life-changing answers faster.
TeleSoftas is a company operating in Lithuania that provides smart and innovative IT solutions, which has been contributing to the improvement of this platform since June 2020. A team of Lithuanian specialists is helping the UK-based company to further develop new features for the platform based on automation and artificial intelligence functionalities that will allow researchers to automate many of the manual processes involved in genomic data analysis.
“On average, people with genetic diseases wait five years for a diagnosis. The solution we have developed will help researchers find ways to reduce this diagnostic odyssey to just a few days, by allowing for faster delivery of actionable genomic information to a larger number of people. Therefore, we truly value this new partnership and believe that this group of highly skilled professionals will help us create an even more innovative platform,” said Rob Denison, CIO at Congenica.
“This partnership gives us an opportunity to use our existing IT knowledge to create a solution that contributes to the treatment of diseases around the world. At the end of 2020 we had a team of 15 engineers working on the project and we are planning to further grow our team in 2021. We will focus on developing new functions for the Congenica rare diseases support platform and improving the backend solutions,” said Gabrielė Navagrudskaitė, TeleSoftas Account Manager.
Genomics is a branch of biological science that focuses on genetically encoded information and allowing this knowledge to be put into practice.
The automation and artificial intelligence functionalities available on the Congenica platform provide users with the possibility to achieve results in minutes, by obtaining and systematising information which previously took several days. This drastically reduces both the time and cost of information processing, while increasing productivity by 95 per cent.
Unlike other software, Congenica allows for a consistent secondary and tertiary analysis of the entire genome and gene group data, as well as the calculation of coverage statistics for all genes, which allows for greater confidence in the resulting data. By analysing the entire human genome, it becomes possible not only to find the problem but also to look at it more broadly, by gathering billions of pieces of data that assist in understanding every important detail within the human genome.
Congenica has already established a diverse customer network spanning 20 countries, including hospitals, diagnostic laboratories, academic medical centres and pharmaceutical companies. The company’s cloud-based business model has a potential for further global expansion as Congenica has recently raised $50million (£39m) in a Series C funding round. Financing will help to advance the company’s international market development and accelerate its flagship genomic analysis software. It also brings new strategic capabilities to drive the commercialisation of rare and inherited cancer applications as well as expansion into oncology, wellness and pharma collaborations.
Congenica is working towards a future where genomics is fully integrated into healthcare services and personalised decisions and treatments.
Thanks for reaching out to us, this means a lot! We will get back to you shortly.
Meanwhile, we invite you to discover what’s new in the Lithuanian business landscape.